Eurofins Scientific SE Stock
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Paris
03:55:00 11/11/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 87.76 EUR | +0.60% |
|
-0.30% | +40.64% |
| 09/11 | Fitch Affirms Eurofins Scientific on Strong Business Risk Profile | MT |
| 27/10 | Eurofins Scientific, Heading for a Sixth Consecutive Gain |  |
| Market Cap | 14.99B 16.71B 13.81B 12.55B 23.74B 1,567B 24.41B 165B 65.9B 840B 62.72B 61.39B 2,654B | P/E 2026 * |
28.7x | P/E 2027 * | 22.8x |
|---|---|---|---|---|---|
| Enterprise Value | 18.42B 20.54B 16.97B 15.41B 29.17B 1,925B 29.99B 203B 80.97B 1,032B 77.07B 75.44B 3,261B | EV / Sales 2026 * |
2.43x | EV / Sales 2027 * | 2.25x |
| Free-Float |
60.34% | Yield 2026 * |
0.91% | Yield 2027 * | 1.04% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ERF | Real-time | |
CBOE
| Real-time | ||
|
OTC Markets
| ERFSF | Delayed | |
|
Tradegate
| ESF0 | Real-time | |
|
Boerse Muenchen
| ESF0 | Real-time | |
|
Xetra
| ESF0 | Delayed | |
|
Deutsche Boerse AG
| ESF0 | Delayed | |
|
London S.E.
| 0MV5 | Delayed | |
|
CBOE
| 0MV5 | Real-time | |
|
Börse Stuttgart
| ESF0 | Delayed | |
|
Wiener Boerse
| ESF | End-of-day quote | |
|
Borsa Italiana
| 4ERF | End-of-day quote |
Last Transcript: Eurofins Scientific SE
| 1 day | +0.60% | ||
| 1 week | -0.30% | ||
| Current month | +0.05% | ||
| 1 month | +13.80% | ||
| 3 months | +25.73% | ||
| 6 months | +47.89% | ||
| Current year | +40.64% |
| 1 week | 86.38 |  | 89.28 |
| 1 month | 76.74 | | 89.28 |
| Current year | 56.84 | | 89.28 |
| 1 year | 54.86 | | 89.28 |
| 3 years | 39.47 | | 89.28 |
| 5 years | 39.47 | | 118.12 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 01/01/1987 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 01/01/2015 |
Christian Wurst
PRN | Corporate Officer/Principal | 54 | 01/10/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 01/01/1987 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 01/01/2015 |
Valérie Hanote
BRD | Director/Board Member | 60 | 01/01/1990 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 27/4/26 | Buy | 700 | 0.0004% | |||
| 19/4/26 | Sell | Chief Financial Officer | 3,000 | 0.0016% | ||
| 19/4/26 | Exercice | Executive/Senior Manager | 700 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.60% | -0.30% | +50.58% | +70.87% | 16.69B | |
| +0.01% | +11.10% | +60.83% | +70.43% | 68.22B | |
| +1.22% | +10.23% | +18.35% | +87.67% | 59.82B | |
| +0.24% | +1.97% | +24.62% | +94.87% | 56.07B | |
| +1.60% | +19.44% | +28.80% | +112.95% | 47.67B | |
| -1.32% | +4.78% | +29.15% | +40.40% | 45.95B | |
| -3.54% | -0.60% | +207.76% | +879.50% | 43.29B | |
| -3.33% | +5.73% | +23.28% | +47.32% | 35.66B | |
| -2.19% | -3.16% | +93.83% | +63.14% | 34.73B | |
| +2.92% | +14.41% | -37.74% | +403.12% | 25.47B | |
| Average | -0.38% | +4.72% | +49.95% | +187.03% | 43B | |
| Weighted average by Cap. | -0.37% | +5.16% | +51.45% | +175.32% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.57B 8.44B 6.97B 6.33B 11.99B 791B 12.32B 83.51B 33.27B 424B 31.67B 31B 1,340B | 8.02B 8.95B 7.39B 6.71B 12.71B 839B 13.06B 88.52B 35.27B 449B 33.57B 32.86B 1,420B |
| Net income | 547M 610M 504M 458M 866M 57.19B 891M 6.04B 2.4B 30.64B 2.29B 2.24B 96.86B | 675M 753M 622M 565M 1.07B 70.6B 1.1B 7.45B 2.97B 37.83B 2.83B 2.77B 120B |
| Net Debt | 3.43B 3.82B 3.16B 2.87B 5.43B 358B 5.58B 37.83B 15.07B 192B 14.35B 14.04B 607B | 3.08B 3.43B 2.84B 2.58B 4.88B 322B 5.01B 33.97B 13.53B 172B 12.88B 12.61B 545B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/11/26 | EUR 87.76 | +0.60% | 238,861 |
| 09/11/26 | EUR 87.24 | -1.58% | 289,064 |
| 06/11/26 | EUR 88.64 | -0.45% | 326,537 |
| 05/11/26 | EUR 89.04 | +1.16% | 265,720 |
| 04/11/26 | EUR 88.02 | +0.89% | 373,855 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Select your edition
All financial news and data tailored to specific country editions
